Evidence map›Paper›PMID 35487285›Full record

ReviewPharmacology & therapeutics2022

Clinical advances in oncolytic virotherapy for pediatric brain tumors.

Gelare Ghajar-Rahimi, Kyung-Don Kang, Stacie K Totsch, Sam Gary, Abbey Rocco, Sarah Blitz, Kara Kachurak, M R Chambers, Rong Li, Elizabeth A Beierle and 5 more

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmacology & therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
8.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 49 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Oncolytic virotherapy and tumor microenvironment modulation.Clinical and experimental medicine · 2025
    Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Gelare Ghajar-RahimiMedical Scientist Training Program, University of Alabama at Birmingham, Birmingham, AL, USA.
Kyung-Don KangDivision of Pediatric Hematology and Oncology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA.
Stacie K TotschDivision of Pediatric Hematology and Oncology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA.
Sam GaryMedical Scientist Training Program, University of Alabama at Birmingham, Birmingham, AL, USA.
Abbey RoccoDivision of Pediatric Hematology and Oncology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA.
Sarah BlitzHarvard Medical School, Boston, MA, USA.
Kara KachurakDivision of Pediatric Hematology and Oncology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA.
M R ChambersDepartment of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, USA.
Rong LiDepartment of Pathology, University of Alabama at Birmingham, and Children's of Alabama, Birmingham, AL, USA.
Elizabeth A BeierleDivision of Pediatric Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA.
Asim BagDepartment of Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, TN, USA.
James M JohnstonDepartment of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, USA.
James M MarkertDepartment of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, USA.
Joshua D BernstockDepartment of Neurosurgery, Brigham and Women's Hospital and Boston Children's Hospital, Harvard University, Boston, MA, USA. Electronic address: jbernstock@bwh.harvard.edu.
Gregory K FriedmanDivision of Pediatric Hematology and Oncology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA; Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: gfriedman@uabmc.edu.
University of Alabama at Birmingham · USBoston Children's Hospital · USHarvard University · USSt. Jude Children's Research Hospital · US

Funding

Tasquinimod as an adjunct to immunotherapies administered peri-operativelyU19CA264512 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI Behnam Badie · 2021 to 2026
$6.0M
Oncolytic Immunotherapy using Chimeric HSV C134: A Phase I Trial and Establishment of Response Indicators in Recurrent Glioma PatientsR01CA222903 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI CASSADY, KEVIN A, MARKERT, JAMES M · 2018 to 2020
$1.7M
A Phase 1 Study of M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma.R01CA217179 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI GILLESPIE, G. YANCEY, MARKERT, JAMES M · 2017 to 2019
$1.6M
Ph1 Study of HSV G207 in Pediatric Malignant Cerebellar Tumors IND 16294 01/05/18.R01FD006368 · FDA · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GREGORY K FRIEDMAN · 2019 to 2026
$750k
Ph1 of HSV G207 and Radiation to Treat Pediatric Brain Tumors IND16294 (12/10/14)R01FD005379 · FDA · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI FRIEDMAN, GREGORY K · 2016 to 2018
$750k
FDA HHS R01 FD005379FDA HHS R01 FD006368NCI NIH HHS R01 CA217179NCI NIH HHS R01 CA222903NCI NIH HHS U19 CA264512
6 · The paper itself

Abstract

Malignant brain tumors constitute nearly one-third of cancer diagnoses in children and have recently surpassed hematologic malignancies as the most lethal neoplasm in the pediatric population. Outcomes for children with brain tumors are unacceptably poor and current standards of care-surgical resection, chemotherapy, and radiation-are associated with significant long-term morbidity. Oncolytic virotherapy has emerged as a promising immunotherapy for the treatment of brain tumors. While the majority of brain tumor clinical trials utilizing oncolytic virotherapy have been in adults, five viruses are being tested in pediatric brain tumor clinical trials: herpes simplex virus (G207), reovirus (pelareorep/Reolysin), measles virus (MV-NIS), poliovirus (PVSRIPO), and adenovirus (DNX-2401, AloCELYVIR). Herein, we review past and current pediatric immunovirotherapy brain tumor trials including the relevant preclinical and clinical research that contributed to their development. We describe mechanisms by which the viruses may overcome barriers in treating pediatric brain tumors, examine challenges associated with achieving effective, durable responses, highlight unique aspects and successes of the trials, and discuss future directions of immunovirotherapy research for the treatment of pediatric brain tumors.

Indexed as

Brain NeoplasmsOncolytic VirotherapyAdenoviridaeAdultChildHumansImmunotherapyBrain tumorsGliomaImmunotherapyOncolyticPediatricVirotherapy

Identifiers

PMID35487285
PMCPMC9709696
OpenAlexW4224442594

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.